Press Releases Keros Therapeutics, Inc.

Equities

KROS

US4923271013

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
54.27 ^USD	-5.78%		-10.40%	+36.49%

May. 08	Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q1 Revenue $83,000	MT
May. 08	Keros Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results	May. 08	AQ
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes	Mar. 14	AQ
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference	Mar. 05	AQ
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	Feb. 28	AQ
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress	Jan. 29	AQ
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock	Jan. 09	AQ
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock	Jan. 03	AQ
Keros Therapeutics Announces Proposed Public Offering of Common Stock	Jan. 03	AQ
Keros Therapeutics to Develop KER-065 for the Treatment of Obesity	Jan. 03	AQ
Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition	Dec. 11	AQ
Keros Therapeutics to Present at Upcoming Healthcare Conferences	Nov. 07	AQ
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results	Nov. 06	AQ
Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition	Nov. 02	AQ
Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society	23-10-04	AQ
Keros Therapeutics to Present at Upcoming Healthcare Conferences	23-09-05	AQ
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results	23-08-07	AQ
Keros Therapeutics : KER-012 Investor Call Deck August 2023	23-08-03	PU
Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension	23-07-24	AQ
Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference	23-06-12	AQ
Keros Therapeutics : Hematology Franchise Investor Call Presentation	23-06-09	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Keros Therapeutics, Inc.

Equities

KROS

US4923271013

Press Releases

Filters